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Foreword
“Nature abhors a vacuum,” but does it always assign a func-
tion to all peptides produced in the body? When I started my
career in Neuroendocrinology I learned that there were many
physiologic functions for which no peptide or hormone had
been found, many peptides for which no physiologic function
had been established, that certain peptides simply served as
markers but had no function and others had established func-
tions. Yet, as techniques evolved to probe in greater depth into
the mysteries of the human body new functions were being
discovered. It seems now that C-peptide may fulﬁll this last
category.
The connecting peptide or C-Peptide was ﬁrst described by
Steiner (1967) in Chicago as a byproduct of insulin biosynthe-
sis.TheC-peptidelinkstheinsulinAandBchainsinproinsulin,
providingtherebyameanstopromotetheirefﬁcientfoldingand
assembly in the endoplasmic reticulum during insulin biosyn-
thesis. It further facilitates the intracellular transport, sorting
and proteolytic processing of proinsulin into biologically ac-
tiveinsulininthematuresecretorygranulesoftheBcellsofthe
isletsofLangerhans.C-peptidefunctionstoallowproperalign-
ment of the A and B chains of insulin and is stored in the solu-
ble compartment of the secretory granules in association with
chromogranin and IAPP and a number of the proinsulin/insulin
intermediates such as those cleaved by the prohormone conver-
tasesPC2andPC1/3.TheyinturncleaveinsulinfromtheBand
A chains of insulin respectively. C-peptide in mammalians is
about31aminoacidslongandhasacentralglycine-richregion,
which allows it to fold like a concertina, permitting the appro-
priate alignment of the A and B chains for insulin to form its
disulﬁde bonds and achieve its tertiary structure. Remarkably,
theevolutionaryrelatedIGFsalsocontainaC-peptide,whichis
shorter in length, but C-peptide in proinsulin has a unique con-
servatism of structure testifying to its important role in peptide
biosynthesis. C-peptide facilitates its own excision from proin-
sulinduringmaturationtoinsulinwithoutwhichtherewouldbe
reducedbiologicalactivityofinsulin.Failureofthisprocessing
is seen as a defect in type two diabetes and the extreme exam-
ple occurs in insulin secreting tumors in which the Proinsulin/
insulin ratio is markedly increased.
For years no biological function was ascribed to C-peptide,
instead the differences in its half-life and its distinction from
beef and porcine C-peptide allowed assays to be developed
which could distinguish epitopes present on the different
C-peptides which allowed measurements even in the presence
of these administered insulins and antibodies The differences
in insulin half life of about 3 minutes vs. that of C-peptide of
around 30 minutes also allowed for single measurements to be
made as a means of reﬂecting upon β cell mass and quanti-
tated insulin secretory rates in vivo as a means of distinction
between type 1 and 2 diabetes. Autonomous insulin overpro-
duction in tumors was evaluated by means of C-peptide sup-
pression tests; latterly, stimulation of C-peptide using meals,
arginineorglucagonhasbeenintroducedintotheclinicalarena
in an attempt to quantitate β cell mass.
The high degree of conservation and overall length of
C-peptidemightargueinfavorofabiologicalactivityoutsideof
insulin processing. This region of proinsulin accepts mutations
at a rate 12–15 times greater than the evolution of both insulin
and the IGFs suggesting that the molecule is not constrained by
a need to interact with speciﬁc target tissues or membrane re-
ceptors. It has been accepted for decades that for any hormone
to exert speciﬁc cellular effects a speciﬁc receptor should be
identiﬁable at the cell surface and that it binds in a saturable,
reversible manner and activates speciﬁc cellular events. The
biologic actions found with C-peptide were ﬁrst explained by
non-chiral interactions with other molecules at the membrane
surface such as insulin for which there appeared to be a manda-
tory need (Ido et al., 1997). The search for a speciﬁc receptor
remainedelusiveuntilRigleretal.(1999)andHenrikssonetal.
(2001) using ﬂuorescence correlation spectroscopy sensitive
enough to detect binding were able to demonstrate “receptors”
on cultured renal tubular cells and saphenous vein endothelial
cells. The binding was inhibited by pertussis toxin suggesting
that binding was in some way coupled to G protein activaton.
Thus, it was suggested that C-peptide signaling included acti-
vation of a speciﬁc pertussis toxin-sensitive G protein coupled
receptor activation of calcium dependent intracellular signal-
ing (Wahren and J¨ ornvall, 2003). The binding of C-peptide has
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an association constant of around 3.109 M−1 and saturation
occurs at 1nM suggesting that a biological role would not be
seen in normal subjects but only those deﬁcient in C-peptide.
It is still, however, not clear whether the actions of C-peptide
are due to the receptor binding or the chiral interactions with
other ligands. C-peptide stimulates glucose transport in human
skeletal muscle (Zierath et al., 1996), increases glycogen syn-
thesisandaminoaciduptakeinL6myoblasts(Grunbergeretal.,
2001), enhances NA+,K+-ATPase activity in rat sciatic nerve,
granulation tissue, red blood cells, pancreatic islets, renal cells
and other tissues. More importantly it activates endothelial ni-
tric oxide synthase releasing NO from bovine aortic endothe-
lial cells (Wahren et al., 2000). Nonetheless, it is clear that
C-peptide alone or in combination with a permissive amount of
insulin mimics several of insulin’s effects. In insulin sensitive
myocytes (L6 myoblasts), differentiated myocytes, adipocytes,
neuroblastoma cells the signal pathways of C-peptide are sim-
ilar to those of insulin-including the predominantly metabolic
pathwaysinvolvingPI-3kinaseandthegrowthpromotingpath-
ways involving MAP kinases. The receptor through which the
C-peptide activities are transmitted remains elusive and will be
an important program for future elucidation if C-peptide is to
enter a biologic market. Nonetheless a number of physiologi-
cal functions include stimulation of NA+/K+ ATPase activity,
altered neural and vascular function (Wahren et al., 1994; Ido
et al., 1997; Kitamura et al., 2001). While it still seems un-
likely that C-peptide will bind to lipid rich plasma membranes
there are a number of other means whereby it could modulate
cellular responses and thereby participate in metabolic events,
or growth promoting or anti-apoptotic events important in the
biological stability of man.
There has been fairly uniform agreement that there is a re-
duction in Na+/K+ ATPase activity in red blood cells and other
tissues in diabetes. Vague and colleagues argue cogently that
this is due to the deﬁciency of C-peptide in type 1 diabetes,
that it is corrected by C-peptide administration and is a direct
effect of C-peptide in vitro. This, of course would have impor-
tant ramiﬁcations on endothelial function and red blood cell
deformability which affect tissue oxygenation and is critical to
the viability of many tissues in people with diabetes.
There is a profound reduction in neurovascular perfusion of
peripheral tissues including nutritive ﬂow to skin in diabetes
(Vinik et al., 2001). While this may be a consequence of pro-
longed hyperglycemia, increasing evidence supports the notion
that disturbed blood ﬂow precedes the development of hyper-
glycemia, occurs with impaired glucose tolerance (IGT) and
even in the presence of the dysmetabolic syndrome in which
resistance to the action of insulin is present and cosegregates
with the disordered microvascular function. Fort and Kunt in
thisissuehighlighttheroleofC-peptideinmicrovascularfunc-
tion and demonstrate that it may be feasible to correct the con-
duit (brachial artery, resistance (forearm) and nutritive (ﬁnger)
deﬁcits in blood ﬂow in diabetes with C-peptide. It will, of
course, require carefully designed structures with appropriate
endpoints to validate these observations and clearly it will be
necessary to deﬁne basal C-peptide status if the outcomes are
to prove successful and not hamstrung by lack of appreciation
of this relationship.
There may, however, be additional effects of C-peptide on
microvascular integrity. Increased extracellular matrix protein
deposition and capillary basement membrane thickening are
characteristic features of diabetic retinopathy. It seems that on-
cofetal ﬁbronectin synthesis is increased in retinas of a model
of type 1 diabetes the BB/Wor rat secondary to an increase in
TGF-β and endothelin-1. C peptide abrogates the increase in
oncofetal FN without changing the TGF-β or endothelin tran-
scriptssuggestingaverydistalroleinamelioratingretinopathy.
It was, however, without effect in the BB-ZDR-Wor rat retina
model of type 2 diabetes again emphasizing an action only in
depleted C-peptide models and dictating speciﬁcity in future
study designs.
It has recently been established that the pathogenesis of di-
abetic neuropathies is complex and that no single mechanism
can be held responsible for the manifestations of the diverse
forms of the condition (Cameron et al., 2001; Sima et al., 2003;
Vinik et al., 2004). Moreover, clinical evidence has supported
the notion that C-peptide deﬁciency contributes to the severity
thereof. Animal studies using the BB-Wor as a model of type 1
diabetes and the BB-ZDR-Wor as a model of type 2 diabetes
have further elucidated differences in the pathogenesis of these
conditions (Sima and Shafrir, 2003). As would be expected for
the effects of C-peptide on Na+/K+ ATPase, endothelial NO
and endoneurial blood ﬂow, C-peptide signiﬁcantly prevents
bothmotorandsensorynerveconductionvelocitydeterioration
as well as decreasing thermal hyperalgesia, a function of small
unmyelinatedCﬁbers(Simaetal.,2001;Sima,2003).Theseef-
fectsareonlypartialandinthetype1modelappeartoimprovde
the axonal degeneration and paranodal degenerative changes.
In a small study in humans Ekberg et al. (2003) demonstrated
thatreplacementwithCpeptide(600nmol/day)resultedinsig-
niﬁcant improvement in nerve function with improved sensory
nerve conduction velocities, and vibratory perception thresh-
old within 3 months compared with insulin alone. There is also
an improvement in autonomic function and warm thermal per-
ception thresholds. Again this is due to the “insulinomimetic”
actionofC-peptideanddoesnotoccurwithinsulinalone.These
effects may be mediated by enhancement of endoneurial blood
ﬂow by a NO and not a prostaglandin-mediated mechanism but
appear to be independent of changes in oxidative stress. The
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apparently being mediated directly by NO are likely to be due
to direct effects of C-peptide on neurotophism involving NGF,
its receptors, IGFs, substance P, calcitonin gene related protein
or as yet other non-identiﬁed peptide mediators of pain. The
abilityofC-peptidetorestoredamagednervefunctionsuggests
that it may effectively induce nerve regeneration. In addition a
varietyofgenesandtheirproteinproductshavebeenimplicated
including the early response genes such as a c-fos, cytoskeletal
proteins e.g. laminin, various cytokines e.g. IL-6, restoration
of microﬁlament downregulation and upregulation of tubulin
genes. At the paranode, proteins such as caspr (which inter-
acts with spectrin, actin and contactin) are regulated through
the activity of PI-3 kinases which are down-regulated in the
type 1 diabetes model and correctible with C-peptide. (Sima
etal.,2004).Italsoappearstohavesalutaryeffectsonneuronal
apoptosis thereby providing a rationale for its possible role in
the protection against massive cerebral infarction with strokes
(Li and Sima, 2004). In models of type 2 diabetes, which seem
to exhibit a reduction in endoneurial blood ﬂow and evidence
of oxidative stress, C-peptide appears of fail its ability to al-
ter nerve function nor is there a clear relationship between the
altered endoneurial blood ﬂow and nerve function.
Thusaskeletalpeptidethatonceachievedfameandnotoriety
with the discovery of a pivotal role in regulating hormone se-
cretion may be coming of age and entering the neuroendocrine
stratosphereasausefulmarkerofβ cellintegrity,ausefulmea-
sure to distinguish type 1 from type 2 diabetes as well as the
diagnosis of insulinomas. The provocative data presented in
the accompanying manuscripts are sufﬁcient to tantalize even
the most discerning critical minds into wondering if the deity
in his or her wisdom once again indulged in conservation and
utilized one peptide structure to serve us in more than one way.
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